Table 4.
Relative Risks (RR) ad 95% Confidence Intervals (CI) between baseline serum 25(OH)D levels (nmol/L) and site-specific cancer mortality in the NHANES III study, 1988–2006.*
| <50 | 50–<80 | 80–<100 | ≥100 | P-Trend | |
|---|---|---|---|---|---|
| Lung Cancer† (Men and Women) | |||||
| No. Cases | 86 | 90 | 42 | 34 | |
| RR (95% CI) | 1.0 | 1.09 (0.75–1.57) | 0.99 (0.58–1.70) | 1.50 (0.90–2.52) | 0.15 |
| Men | |||||
| No. Cases | 52 | 52 | 30 | 31 | |
| RR (95% CI) | 1.0 | 0.93 (0.58–1.49) | 1.19 (0.74–1.92) | 1.87 (1.04–3.34) | 0.03 |
| Women | <50 | 50–<80 | ≥80 | ||
| No. Cases | 34 | 38 | 15 | ||
| RR (95% CI) | 1.0 | 1.35 (0.73–2.48) | 0.64 (0.23–1.79) | 0.34 | |
| Colorectal Cancer‡ (Men and Women) | <50 | 50–<80 | 80–<100 | ≥100 | |
| No. Cases | 38 | 34 | 14 | 9 | |
| RR (95% CI) | 1.0 | 0.56 (0.29–1.09) | 0.61 (0.26–1.47) | 0.35 (0.11–1.14) | 0.09 |
| Men | <50 | 50–<80 | ≥80 | ||
| No. Cases | 22 | 23 | 16 | ||
| RR (95% CI) | 1.0 | 0.61 (0.24–1.57) | 0.71 (0.25–1.99) | 0.26 | |
| Women | |||||
| No. Cases | 16 | 11 | 17 | ||
| RR (95% CI) | 1.0 | 0.55 (0.21–1.45) | 0.37 (0.11–1.27) | 0.23 | |
| Other Digestive Cancers§ (Men and Women) | |||||
| No. Cases | 36 | 51 | 31 | ||
| RR (95% CI) | 1.0 | 1.69 (0.77–3.74) | 1.31 (0.61–2.81) | 0.15 | |
| Men | |||||
| No. Cases | 20 | 29 | 23 | ||
| RR (95% CI) | 1.0 | 1.72 (0.76–3.88) | 1.61 (0.75–3.47) | 0.01 | |
| Women | |||||
| No. Cases | 16 | 22 | 8 | ||
| RR (95% CI) | 1.0 | 1.72 (0.58–5.10) | 0.99 (0.31–3.11) | 0.47 | |
| Female Breast | |||||
| No. Cases | 24 | 19 | 10 | ||
| RR (95% CI) | 1.0 | 0.94 (0.40–2.20) | 0.65 (0.18–2.38) | 0.56 | |
| Prostate Cancer | |||||
| No. Cases | 16 | 38 | 20 | ||
| RR (95% CI) | 1.0 | 1.39 (0.70–2.76) | 1.23 (0.50–3.05) | 0.84 | |
| NHL/Leukemia (Men and Women) | |||||
| No. Cases | 17 | 25 | 16 | ||
| RR (95% CI) | 1.0 | 0.92 (0.44–1.92) | 1.10 (0.40–2.98) | 0.96 | |
| Miscellaneous Cancers¶ (Men and Women) | |||||
| No. Cases | 73 | 108 | 53 | ||
| RR (95% CI) | 1.0 | 1.66 (1.06–2.60) | 1.36 (0.71–2.59) | 0.90 | |
| Men | |||||
| No. Cases | 28 | 58 | 28 | ||
| RR (95% CI) | 1.0 | 1.04 (0.50–2.16) | 0.83 (0.33–2.29) | 0.40 | |
| Women | |||||
| No. Cases | 45 | 50 | 25 | ||
| RR (95% CI) | 1.0 | 2.15 (1.12–4.15) | 1.85 (0.74–4.64) | 0.39 |
*
Adjusted for age, gender, race/ethnicity, smoking history and BMI, using Cox proportional hazards regression.
†
Includes cancers of the lung, trachea and bronchus.
‡
Includes colorectal and anal cancer mortality.
§
Includes esophageal, stomach, liver, pancreatic cancer.
¶
Includes cancers of the buccal cavity, larynx, melanoma, gynecological sites, kidney, bladder, brain, multiple myeloma, and others.